دورية أكاديمية
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
| العنوان: | Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers |
|---|---|
| المؤلفون: | Fuca G., Cohen R., Lonardi S., Shitara K., Elez M. E., Fakih M., Chao J., Klempner S. J., Emmett M., Jayachandran P., Bergamo F., Garcia M. D., Mazzoli G., Provenzano L., Colle R., Svrcek M., Ambrosini M., Randon G., Shah A. T., Salati M., Fenocchio E., Salvatore L., Chida K., Kawazoe A., Conca V., Curigliano G., Corti F., Cremolini C., Overman M., Andre T., Pietrantonio F. |
| المساهمون: | Fuca, G., Cohen, R., Lonardi, S., Shitara, K., Elez, M. E., Fakih, M., Chao, J., Klempner, S. J., Emmett, M., Jayachandran, P., Bergamo, F., Garcia, M. D., Mazzoli, G., Provenzano, L., Colle, R., Svrcek, M., Ambrosini, M., Randon, G., Shah, A. T., Salati, M., Fenocchio, E., Salvatore, L., Chida, K., Kawazoe, A., Conca, V., Curigliano, G., Corti, F., Cremolini, C., Overman, M., Andre, T., Pietrantonio, F. |
| سنة النشر: | 2022 |
| المجموعة: | ARPI - Archivio della Ricerca dell'Università di Pisa |
| مصطلحات موضوعية: | gastrointestinal neoplasm, immunotherapy, translational medical research, tumor biomarkers |
| الوصف: | Background Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary resistance or short-term disease control. Since malignant effusions represent an immune-suppressed niche, we investigated whether peritoneal involvement with or without ascites is a poor prognostic factor in patients with dMMR/MSI-H metastatic colorectal cancer (mCRC) and gastric cancer (mGC) receiving ICIs. Methods We conducted a global multicohort study at Tertiary Cancer Centers and collected clinic-pathological data from a cohort of patients with dMMR/MSI-H mCRC treated with anti-PD-(L)1 ±anti-CTLA-4 agents at 12 institutions (developing set). A cohort of patients with dMMR/MSI-high mGC treated with anti-PD-1 agents±chemotherapy at five institutions was used as validating dataset. Results The mCRC cohort included 502 patients. After a median follow-up of 31.2 months, patients without peritoneal metastases and those with peritoneal metastases and no ascites had similar outcomes (adjusted HR (aHR) 1.15, 95% CI 0.85 to 1.56 for progression-free survival (PFS); aHR 0.96, 95% CI 0.65 to 1.42 for overall survival (OS)), whereas inferior outcomes were observed in patients with peritoneal metastases and ascites (aHR 2.90, 95% CI 1.70 to 4.94; aHR 3.33, 95% CI 1.88 to 5.91) compared with patients without peritoneal involvement. The mGC cohort included 59 patients. After a median follow-up of 17.4 months, inferior PFS and OS were reported in patients with peritoneal metastases and ascites (aHR 3.83, 95% CI 1.68 to 8.72; aHR 3.44, 95% CI 1.39 to 8.53, respectively), but not in patients with only peritoneal metastases (aHR 1.87, 95% CI 0.64 to 5.46; aHR 2.15, 95% CI 0.64 to 7.27) when compared with patients without peritoneal involvement. Conclusions Patients with dMMR/MSI-H gastrointestinal cancers with peritoneal metastases and ascites should be considered as a ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/35110358; info:eu-repo/semantics/altIdentifier/wos/WOS:000758164800002; volume:10; issue:2; numberofpages:13; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; https://hdl.handle.net/11568/1132688Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85124058744; https://jitc.bmj.com/content/10/2/e004001Test |
| DOI: | 10.1136/jitc-2021-004001 |
| الإتاحة: | https://doi.org/10.1136/jitc-2021-004001Test https://hdl.handle.net/11568/1132688Test https://jitc.bmj.com/content/10/2/e004001Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.DB2C29FE |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/jitc-2021-004001 |
|---|